Navigation Links
MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- MolecularHealth, Inc., a leader in clinico-molecular informatics™, today announced the establishment of a five-year research collaboration agreement with the U.S. Food and Drug Administration (FDA) to evaluate and refine MolecularHealth's Molecular Analysis of Side Effects (MASE), a software system intended to support mechanism-based drug safety assessment and prediction.

The FDA's Center for Drug Evaluation and Research (CDER) will work with MolecularHealth to incorporate non-proprietary molecular and clinical endpoints of regulatory interest into MASE, along with non-proprietary information on patient populations, drug promiscuity, molecular modes of action and mechanisms of disease.

"We are pleased to collaborate with the FDA to obtain their input into the evaluation of the analytical power of MASE for assessing drug safety in the U.S.," said Jeffrey D. Marrazzo, chief business officer of MolecularHealth. "MASE has the potential to benefit pharmaceutical developers, regulators and clinicians alike, helping them to develop and monitor drugs in a safer, more efficient manner."

MASE uses information about drug modes of action and the molecular implications of interacting treatments, co-morbidities and genetic profiles to enable a more precise assessment of drug safety. MASE enables the exploration and analysis of adverse event information from both statistical and molecular perspectives and provides analytical and visualization tools to support the detection and validation of drug-related safety issues.

"Drug safety monitoring and detection have become increasingly important and complex endeavors that depend heavily on a static, binary, observational system," said David Jackson, chief scientific officer of MolecularHealth. "We believe that MolecularHealth's predictive approach to understanding the molecular basis of adverse events will complement the agency's current mode of drug safety assessment to advance the promise of precision medicine."

About MolecularHealthMolecularHealth, Inc., a clinico-molecular informatics company, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history and published scientific and medical evidence into safer, more effective drug choices for patients. The company's solutions range from a next generation drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support system that transforms genome sequences into evidence-based treatment strategies for cancer patients. Backed by the co-founder and former chairman and chief executive officer of SAP, Dietmar Hopp, through dievini Hopp BioTech, MolecularHealth maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York. The company is led by a team of seasoned entrepreneurs, including the founding members of Generation Health, LION Bioscience, Model N Life Sciences and Xapien, and a group of scientists and technologists instrumental in the development of data analysis software for the Human Genome Project and clinical IT systems for leading U.S. health systems. MolecularHealth's collaborators include the University of Texas MD Anderson Cancer Center and the U.S. Food and Drug Administration (FDA).Media Contacts

Corporate Contact 

 Tony Russo, Ph.D., or Matt Middleman, M.D.Eric M. StoneRusso Partners, LLC

Vice President, Sales and MarketingT: 212-845-4251

T: (713) 834-9990T: 212-845-4272



SOURCE MolecularHealth
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
2. BioNeutral and Barnabas Health to Collaborate for Surgical Instrument Sterilization
3. Mercy/ROi and BD Collaborate to Improve Quality of Care and Reduce Costs
4. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
5. UCSF, Sanofi Collaborate to Find New Diabetes Cures
6. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
7. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
8. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
9. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
10. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
11. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... 2015  The migration to value-based care will ... plans that help patients stay healthy and reduce ... digitally enabled, incorporate care guidelines and be reflective ... will also allow all stakeholders to collaborate across ... optimal. That is the vision, however, research by ...
(Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... limb amputations in the United States. Podiatrists are well aware that psychology-based patient ... therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... 01, 2015 , ... PartnerTech , a leader in ... since 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director ... amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. He ...
(Date:12/1/2015)... ... 2015 , ... SonaCare Medical congratulates the University College London ... on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative ... medical landscape. , The UCLH team won the award for their innovative approach ...
Breaking Medicine News(10 mins):